{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:11:06Z","timestamp":1762913466469,"version":"3.45.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jvacx.2024.100448","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T22:16:09Z","timestamp":1706048169000},"page":"100448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["SARS-CoV-2 vaccines in China could reduce COVID-19-related respiratory syndromes and deaths: A retrospective cohort study"],"prefix":"10.1016","volume":"16","author":[{"given":"Weiping","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-1861","authenticated-orcid":false,"given":"Chuanbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jvacx.2024.100448_b0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100448_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","article-title":"Risk factors for Covid-19 severity and fatality: a structured literature review","volume":"49","author":"Wolff","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jvacx.2024.100448_b0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.addr.2021.01.014","article-title":"SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?","volume":"172","author":"Chakraborty","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100448_b0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05992-1","article-title":"Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality","volume":"21","author":"Flook","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100448_b0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10287","key":"10.1016\/j.jvacx.2024.100448_b0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2024.100448_b0035","doi-asserted-by":"crossref","unstructured":"Richardson VL, Camacho Franco MA, Bautista M\u00e1rquez A, et al. Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers-Mexico, March-December 2021. Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S167-s173.","DOI":"10.1093\/cid\/ciac488"},{"issue":"38","key":"10.1016\/j.jvacx.2024.100448_b0040","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"10.1016\/j.jvacx.2024.100448_b0045","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.vaccine.2022.02.039","article-title":"Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)","volume":"40","author":"Ismail AlHosani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100448_b0050","doi-asserted-by":"crossref","unstructured":"Premikha M, Chiew CJ, Wei WE, et al. Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore. Clin Infect Dis. 2022 Oct 12;75(8):1442-1445.","DOI":"10.1093\/cid\/ciac288"},{"key":"10.1016\/j.jvacx.2024.100448_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijid.2021.08.052","article-title":"Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose","volume":"112","author":"Vicenti","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100448_b0060","article-title":"A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern","volume":"3","author":"van Gils","year":"2022","journal-title":"Cell Rep Med"},{"issue":"7867","key":"10.1016\/j.jvacx.2024.100448_b0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jvacx.2024.100448_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.778243","article-title":"Previous COVID-19 Infection and Antibody Levels After Vaccination","volume":"9","author":"Ali","year":"2021","journal-title":"Front Public Health"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100448_b0075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","article-title":"Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner","volume":"29","author":"Keeton","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jvacx.2024.100448_b0080","unstructured":"COVID-19 virus vaccination status. Official website of the National Health and Wellness Commission of the People's Republic of China. 2022 December 24 [Cited 2023 April 01]. Available from: http:\/\/www.nhc.gov.cn\/xcs\/yqjzqk\/202212\/a87d93dbfbd14fc1b7837f1a20092cbe.shtml."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100448_b0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100448_b0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100448_b0095","doi-asserted-by":"crossref","unstructured":"Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. Bmj. 2021 Aug 20;374:n2015.","DOI":"10.1136\/bmj.n2015"},{"key":"10.1016\/j.jvacx.2024.100448_b0100","unstructured":"Health Commission website. Notice on the issuance of the diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9). National Health Office Medical Letter [2022] No. 71. 2022 Match 14 [Cited 2023 June 15]. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2022-03\/15\/content_5679257.htm."},{"issue":"21","key":"10.1016\/j.jvacx.2024.100448_b0105","first-page":"2082","article-title":"Overview of the efficacy and safety of a new coronavirus pneumonia vaccine","volume":"31","author":"Yang","year":"2022","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1016\/j.jvacx.2024.100448_b0110","unstructured":"SU JF; Jing L; Zhou WX. Analysis of new coronavirus vaccine development and production in China: an example of inactivated vaccine. South China Prevent Med 2021;47(07):861-864."}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:08:05Z","timestamp":1762913285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":22,"alternative-id":["S2590136224000214"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100448","relation":{},"ISSN":["2590-1362"],"issn-type":[{"type":"print","value":"2590-1362"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 vaccines in China could reduce COVID-19-related respiratory syndromes and deaths: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100448"}}